Special Issue "Exploiting the Specialization of the Blood–Brain Barrier to Deliver Therapies to the Brain"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 31 July 2023 | Viewed by 160

Special Issue Editor

Molecular Bionics Laboratory, Institute for Bioengineering of Catalonia (IBEC), 08028 Barcelona, Spain
Interests: blood–brain barrier; targeting strategies; nanocarriers; transcytosis; neurodegeneration; neuroinflammation

Special Issue Information

Dear Colleagues,

Overcoming the blood–brain barrier (BBB) to efficiently deliver theranostics to the brain will revolutionize the diagnosis and treatment of neurological disorders.

We would like to extend an invitation to contribute to this Special Issue focusing on exploring the specialized phenotype of brain endothelial cells, understanding transcytosis mechanisms across the BBB, and identifying how this knowledge may guide the development of delivery strategies with enhanced brain targeting and delivery efficiency.

In this Special Issue, original research articles and reviews are welcome in research areas including (but not limited to): brain endothelial cell physiology specialization (e.g., tight junction stability, cell-surface protein dynamics, glycocalyx variations, endocytic activity modulation, arterio-venous differentiation); cell trafficking mechanisms governing transcytosis (e.g., ligand–receptor affinity, intracellular protein mediators, vesicular tubulation, endosomal escape); modulation of BBB function by the neurovascular unit; and innovative drug delivery strategies exploiting these characteristics.

We aim to establish a focus point to foment the development of next-generation brain targeting strategies which embrace the physiology of the BBB for the improved delivery of therapies into the brain.

I look forward to receiving your contributions.

Dr. Daniel Gonzalez Carter
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • blood–brain barrier
  • neurovascular unit specialization
  • endothelial transcytosis
  • brain targeting
  • drug delivery
  • innovative delivery systems
  • nanoparticles
  • brain disorders

Published Papers

This special issue is now open for submission.
Back to TopTop